Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
Oruka Therapeutics (Nasdaq: ORKA), a biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its upcoming participation at Piper Sandler's 36th Annual Healthcare Conference. The company will engage in a fireside chat scheduled for Tuesday, December 3rd, 2024, at 3:00 PM ET.
Oruka Therapeutics (Nasdaq: ORKA), un'azienda biotecnologica impegnata nello sviluppo di nuovi biologici per malattie dermatologiche croniche come la psoriasi a placche, ha annunciato la sua prossima partecipazione alla 36ª Conferenza Sanitaria Annuale di Piper Sandler. L'azienda parteciperà a un incontro informale programmato per martedì 3 dicembre 2024, alle 15:00 ET.
Oruka Therapeutics (Nasdaq: ORKA), una empresa biotecnológica centrada en el desarrollo de nuevos biológicos para enfermedades dérmicas crónicas como la psoriasis en placas, ha anunciado su próxima participación en la 36ª Conferencia Anual de Salud de Piper Sandler. La empresa participará en una charla informal programada para el martes 3 de diciembre de 2024, a las 3:00 PM ET.
Oruka Therapeutics (Nasdaq: ORKA)는 판상 건선을 포함한 만성 피부 질환을 위한 새로운 생물 의약품 개발에 중점을 둔 생명공학 회사로, Piper Sandler의 제36회 연례 헬스케어 컨퍼런스에 참석할 예정임을 발표했습니다. 회사는 2024년 12월 3일 화요일 오후 3시(ET)에 예정된 편안한 대화에 참여할 것입니다.
Oruka Therapeutics (Nasdaq: ORKA), une entreprise biotechnologique axée sur le développement de nouveaux biologiques pour les maladies cutanées chroniques, y compris la psoriasis en plaques, a annoncé sa prochaine participation à la 36ème Conférence Annuelle sur la Santé de Piper Sandler. L'entreprise participera à une discussion informelle prévue pour le mardi 3 décembre 2024, à 15h00 ET.
Oruka Therapeutics (Nasdaq: ORKA), ein Biotech-Unternehmen, das sich auf die Entwicklung neuartiger Biologika für chronische Hauterkrankungen wie Plaque-Psoriasis konzentriert, hat seine bevorstehende Teilnahme an der 36. jährlichen Healthcare-Konferenz von Piper Sandler angekündigt. Das Unternehmen wird an einem informellen Gespräch teilnehmen, das für Dienstag, den 3. Dezember 2024, um 15:00 Uhr ET geplant ist.
- None.
- None.
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced participation and a fireside chat at Piper Sandler’s 36th Annual Healthcare Conference:
Date: Tuesday, December 3rd, 2024
Time: 3:00PM ET
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
FAQ
When is Oruka Therapeutics (ORKA) presenting at the Piper Sandler Healthcare Conference 2024?
What medical conditions does Oruka Therapeutics (ORKA) focus on treating?
What type of presentation will Oruka Therapeutics (ORKA) give at the Piper Sandler Conference?
Which healthcare conference is Oruka Therapeutics (ORKA) attending in December 2024?
